Zaman Ashraf

Zaman Ashraf


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 July 2024 in RSC Advances
Verified
Journal Article
Open access
PDF file
MAManazza Afzal
Manazza Afzal
RMRabia Mehmood
Rabia Mehmood
EMEhsan Ullah Mughal
Ehsan Ullah Mughal
NNNafeesa Naeem
Nafeesa Naeem
ZAZaman Ashraf
Zaman Ashraf
ASAmina Sadiq
Amina Sadiq
In this study, a series of novel bis-pyrimidine derivatives (1P–8P) were designed, synthesized, characterized, and investigated for their in vitro inhibitory activity against mushroom tyrosinase.

26 March 2025
Verified
Book Chapter
Closed access
PDF file
Zakir UllahZakir Ullah
Zakir Ullah
JIJaved Iqbal
Javed Iqbal
BABanzeer Ahsan Abbasi
Banzeer Ahsan Abbasi
Iftikhar AliIftikhar Ali
Iftikhar Ali
SIShumaila Ijaz
Shumaila Ijaz
TMTariq Mahmood
Tariq Mahmood

1 May 2026 in Drug Design, Development and Therapy
Verified
Journal Article
Open access
Muhammad LatifMuhammad Latif
Muhammad Latif
SMSana Mazhar
Sana Mazhar
MTMussarat Tasleem
Mussarat Tasleem
AAAbdulmajeed Alqurashi
Abdulmajeed Alqurashi
MAMuhammad Arfan
Muhammad Arfan
MZMuhammad Zafar
Muhammad Zafar
Poly(ADP-ribose) polymerase (PARP) inhibition has emerged as a prominent approach in cancer treatment, leading to the development of several poly(ADP-ribose) polymerase inhibitors (PARPi), which have demonstrated substantial progress in clinical trials and efficacy in the management of ovarian cancer (OC), breast cancer (BC), and solid tumors (STs). These PARPi are approved for several cancers, including BC and OC. Among PARPi, Talazoparib (Talzenna®) is a potent therapy for patients with locally advanced or metastatic BC (mBC) with germline BRCA mutations (gBRCAm) and HER2-negative status, demonstrating the highest potency (IC50 = 0.57 nM), which is 4–10 times lower than that of other PARP inhibitors; olaparib (2.0 nM), rucaparib (1.9 nM), and veliparib (4.7 nM), indicating superior efficacy. This review describes the role of BRCA1/2 in BC and OC, highlighting key discovery milestones and providing an overview of available PARP inhibitors (PARPi) at various stages of development. Additionally, it details the discovery and development of talazoparib, one of the key PARPis, its current clinical status, and therapeutic implications. The latest advancements in talazoparib research, including all related clinical trials (Phase 1–3) for the treatment of BC, OC, and other solid tumors (STs), are also summarized. A comprehensive analysis of all clinical trials involving talazoparib, whether as monotherapy or in combination with other drugs, elucidates its potential to improve clinical outcomes, address drug resistance, and explore synergistic combinations with other PARPi or novel agents, thereby providing insights into the clinical utility of talazoparib.

26 March 2025
Verified
Book Chapter
Closed access
PDF file
SIShumaila Ijaz
Shumaila Ijaz
Zakir UllahZakir Ullah
Zakir Ullah
JIJaved Iqbal
Javed Iqbal
BABanzeer Ahsan Abbasi
Banzeer Ahsan Abbasi
Iftikhar AliIftikhar Ali
Iftikhar Ali
TMTariq Mahmood
Tariq Mahmood

12 January 2026 in Iranian Journal of Science
Verified
Journal Article
Closed access
PDF file
MAMUHAMMAD ATIF
MUHAMMAD ATIF
ZAZaman Ashraf
Zaman Ashraf
FYFarhat Yasmeen
Farhat Yasmeen
MIMuhammad Ishaq
Muhammad Ishaq
MIMuhammad Iqbal
Muhammad Iqbal
YQYasir Hayat Qayyum
Yasir Hayat Qayyum

5 January 2026 in Scientific Reports
Verified
Journal Article
Open access
PDF file
MAMuhammad Atif
Muhammad Atif
ZAZaman Ashraf
Zaman Ashraf
FYFarhat Yasmeen
Farhat Yasmeen
MIMuhammad Iqbal
Muhammad Iqbal
MAMoeen Anjum
Moeen Anjum
The newly fabricated fluorescent organic nanoparticles (FONs) with size 80.94 nm as renowned contender has facile synthesis, robust tunable fluorescence, unique optical properties and great potential in sensing at trace level. The optical properties of fluorescent organic probe depend on the experimental parameters e.g. synthesis routes, doping, solvatochromism, temperature, pH and the types of precursors, which influence the surface state and graphitic carbon-cluster. The incorporation of N-atom modified the intrinsic properties (π–π∗, n–π∗ electronic transition) and caused the change in energy level Δ\(\:{E}_{g}\) from 2.81 eV to 2.43 eV. The fluorescent intensity decreased as increasing or decreasing from pH ~ 7 due to change in extended delocalization. The temperature-dependent florescence response showed differently in different solvents owing to various interactions between surface state of fluorescent organic probe and solvents. The fluorescent organic probe demonstrated excellent qualitative and visual detection of water content in organic solvents due to solvatochromism. This strategy enables the bathochromic shift Δλem in fluorescent organic probe for the generation of multicolor. Moreover, the fluorescent organic probe can be used as a fluorescent ink for anti-counterfeiting. This research aims to provide a detailed examination of experimental parameters as a valuable tool for the synthesis of fluorescent organic nanoparticles FONs.